Mesoblast Limited (Nasdaq: MESO; ASX: MSB) announced it has completed patient treatment in its MSB-DR004 pivotal Phase 3 trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE